Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03738878 · ClinicalTrials.gov registry record · Phase 4
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT03738878: Clinical Trial Phase 4 study, sponsored by Vanderbilt University Medical Center.
NCT03738878 is a Phase 4 study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 4 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03738878, a Phase 4 study, was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to test the hypothesis that combined angiotensin receptor blockade (ARB)/neprilysin (NEP) inhibition potentiates the effects of exogenous bradykinin, substance P, and brain natriuretic peptide (BNP) on forearm blood flow or endothelial tissue-type plasminogen activator (t-PA) release compared to ARB alone. A secondary goal is to determine if there is an interactive effect of ARB/NEP inhibition and dipeptidyl peptidase 4 (DPP4) inhibition on responses to these peptides.
Primary Outcome
Forearm blood flow measured by strain gauge plethysmography before and after intra-arterial peptide infusion
Interventions
- DRUG Valsartan
- DRUG LCZ696
- DRUG Bradykinin
- DRUG Substance P
- DRUG BNP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-11-15 |
| Est. Completion | 2024-12-01 |
| Phase | Phase 4 |
Why NCT03738878 stopped before completion
NCT03738878 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 5 interventions - of which Valsartan is the first listed.
NCT03738878 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03738878 about?
NCT03738878 is a clinical study titled "Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1". The purpose of this study is to test the hypothesis that combined angiotensin receptor blockade (ARB)/neprilysin (NEP) inhibition potentiates the effects of exogenous bradykinin, substance P, and brain natriuretic peptide (BNP) on forearm blood flow or endothelial tissue-type plasminogen activator (...
What is the current status of trial NCT03738878?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2018-11-15. Estimated completion is 2024-12-01.
What interventions are being tested in trial NCT03738878?
The interventions under investigation include: Valsartan (DRUG), LCZ696 (DRUG), Bradykinin (DRUG), Substance P (DRUG), BNP (DRUG).
Who is sponsoring clinical trial NCT03738878?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03738878's enrollment target sits among peer trials
4 1994th of 2000 higher than 6 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI